No Data
No Data
Fractyl Health to Present New Preclinical Obesity Data From Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2
Fractyl Health Presents Compelling Preclinical Data From Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Bank of America Securities Reaffirms Their Buy Rating on Fractyl Health, Inc. (GUTS)
Earnings Call Summary | Fractyl Health(GUTS.US) Q1 2024 Earnings Conference
The following is a summary of the Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript:Financial Performance:Fractyl Health generated revenue from its commercial pilot in Germany in Q1 2024.Re
Express News | Fractyl Health Q1 2024 GAAP EPS $(0.17) Up From $(7.87) YoY, Sales $33.000K Up From $5.000K YoY
Fractyl Health | 10-Q: Quarterly report
No Data